175 related articles for article (PubMed ID: 16187086)
1. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
Choi BS; Sondel PM; Hank JA; Schalch H; Gan J; King DM; Kendra K; Mahvi D; Lee LY; Kim K; Albertini MR
Cancer Immunol Immunother; 2006 Jul; 55(7):761-74. PubMed ID: 16187086
[TBL] [Abstract][Full Text] [Related]
2. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
Albertini MR; Hank JA; Schiller JH; Khorsand M; Borchert AA; Gan J; Bechhofer R; Storer B; Reisfeld RA; Sondel PM
Clin Cancer Res; 1997 Aug; 3(8):1277-88. PubMed ID: 9815810
[TBL] [Abstract][Full Text] [Related]
3. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.
Albertini MR; Gan J; Jaeger P; Hank JA; Storer B; Schell K; Rivest T; Surfus J; Reisfeld RA; Schiller JH; Sondel PM
J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):278-95. PubMed ID: 8877722
[TBL] [Abstract][Full Text] [Related]
4. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
[TBL] [Abstract][Full Text] [Related]
5. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.
Bajorin DF; Chapman PB; Wong G; Coit DG; Kunicka J; Dimaggio J; Cordon-Cardo C; Urmacher C; Dantes L; Templeton MA
Cancer Res; 1990 Dec; 50(23):7490-5. PubMed ID: 2253196
[TBL] [Abstract][Full Text] [Related]
6. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.
Chachoua A; Oratz R; Liebes L; Alter RS; Felice A; Peace D; Vilcek J; Blum RH
J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):132-41. PubMed ID: 7804528
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.
Gilman AL; Ozkaynak MF; Matthay KK; Krailo M; Yu AL; Gan J; Sternberg A; Hank JA; Seeger R; Reaman GH; Sondel PM
J Clin Oncol; 2009 Jan; 27(1):85-91. PubMed ID: 19047298
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
Sondel PM; Hank JA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study.
Ozkaynak MF; Sondel PM; Krailo MD; Gan J; Javorsky B; Reisfeld RA; Matthay KK; Reaman GH; Seeger RC
J Clin Oncol; 2000 Dec; 18(24):4077-85. PubMed ID: 11118469
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effects.
Bukowski RM; Murthy SA; Finke J; Caulfield MJ; Tubbs R; Herzog P; Stanley J; Edinger M; Tuason L; McLain D
J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):273-82. PubMed ID: 8061900
[TBL] [Abstract][Full Text] [Related]
11. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon.
Alpaugh RK; von Mehren M; Palazzo I; Atkins MB; Sparano JA; Schuchter L; Weiner LM; Dutcher JP
Med Oncol; 1998 Sep; 15(3):191-8. PubMed ID: 9819796
[TBL] [Abstract][Full Text] [Related]
12. A phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients.
Sosman JA; Kefer C; Fisher RI; Jacobs CD; Pumfery P; Ellis TM
J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):171-80. PubMed ID: 7613643
[TBL] [Abstract][Full Text] [Related]
13. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.
Murray JL; Kleinerman ES; Jia SF; Rosenblum MG; Eton O; Buzaid A; Legha S; Ross MI; Thompson L; Mujoo K; Rieger PT; Saleh M; Khazaeli MB; Vadhan-Raj S
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):206-17. PubMed ID: 8811495
[TBL] [Abstract][Full Text] [Related]
14. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.
Bernstein ZP; Porter MM; Gould M; Lipman B; Bluman EM; Stewart CC; Hewitt RG; Fyfe G; Poiesz B; Caligiuri MA
Blood; 1995 Nov; 86(9):3287-94. PubMed ID: 7579429
[TBL] [Abstract][Full Text] [Related]
15. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
16. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
Gazit Z; Weiss DW; Shouval D; Yechezkeli M; Schirrmacher V; Notter M; Walter J; Kedar E
Cancer Immunol Immunother; 1992; 35(2):135-44. PubMed ID: 1596937
[TBL] [Abstract][Full Text] [Related]
17. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
19. Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response.
Isacson R; Kedar E; Barak V; Gazit Z; Yurim O; Kalichman I; Ben-Bassat H; Biran S; Schlesinger M; Franks CR
Immunol Lett; 1992 Jul; 33(2):127-34. PubMed ID: 1446917
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
Davis ID; Liu Z; Saunders W; Lee FT; Spirkoska V; Hopkins W; Smyth FE; Chong G; Papenfuss AT; Chappell B; Poon A; Saunder TH; Hoffman EW; Old LJ; Scott AM
Cancer Immun; 2007 Aug; 7():14. PubMed ID: 17705350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
